Drug Profile
Crenezumab - AC Immune/Genentech/Universidad-de-Antioquia
Alternative Names: Anti-Abeta antibody; MABT5102A; R 5490245; RG 7412; RO 5490245Latest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator AC Immune; Universidad de Antioquia
- Developer AC Immune; Genentech; Universidad de Antioquia
- Class Antibodies; Antidementias; Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 15 Feb 2024 Discontinued - Phase-II for Alzheimer's disease in Canada (SC) (Roche pipeline, February 2024)
- 15 Feb 2024 Discontinued - Phase-II for Alzheimer's disease in Colombia (IV) (Roche pipeline, February 2024)
- 15 Feb 2024 Discontinued - Phase-II for Alzheimer's disease in Colombia (SC) (Roche pipeline, February 2024)